Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.
Hunan traditional Chinese medicine maker known for classic patent remedies like Liuwei Dihuang Wan sold nationwide.
In one line: A Chinese heritage-TCM Nature's Bounty.
Moat: narrow (brand). Centuries-old heritage TCM brand name recognized across Chinese pharmacy retail.
Headquarters: Changsha, Hunan, China · Employees: 3,674
Size Jiuzhitang (000989.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.16B, the 1895th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.18 on 18 Nov 2026.
Performance Over six months the shares fell 6.9%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 45.9% over the last twelve months (peer median -0.9%); the operating margin is 19.2% (peer median 0.8%).
Valuation It trades at 22.1× forward earnings against a peer median of 21.3× (6th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.3 points above its cost of capital (5.9% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.79B | CN¥2.21B | CN¥2.35B | CN¥2.94B | CN¥3.01B |
| Revenue growth | — | -6% | -20% | -2% | — |
| Gross profit | CN¥1.72B | CN¥1.25B | CN¥1.31B | CN¥1.70B | CN¥1.67B |
| EBITDA | n/a | CN¥374M | CN¥294M | CN¥409M | CN¥394M |
| Net income | CN¥375M | CN¥223M | CN¥216M | CN¥297M | CN¥358M |
| Free cash flow | CN¥644M | CN¥398M | CN¥137M | CN¥48.6M | CN¥441M |
| Capital expenditure | CN¥75.9M | CN¥40.0M | CN¥72.2M | CN¥72.8M | CN¥96.8M |
| Total debt | CN¥52.3M | CN¥136M | CN¥134M | CN¥186M | CN¥127M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jiuzhitang 000989.SZ | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% |
| Dong-E-E-Jiao 000423.SZ | $4.99B | +1% | +8% | 29% | 17.8× | -3.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000989.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.9% | -1.6% | 8th lowest of 21 |
| 6-month return | -6.9% | -11.8% | 7th highest of 20 |
| Distance from 52-week high | -24.5% | -39.3% | 5th highest of 21 |
| Revenue growth (TTM) | +45.9% | -0.9% | 5th highest of 20 |
| Operating margin | 19.2% | 0.8% | highest of 20 |
| Forward P/E | 22.1× | 21.3× | 6th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | -4.0% | 4.9% | least demanding of 8 |
| Growth delivered (Del g) | -9.0% | +4.2% | 2nd lowest of 8 |
| Hurdle (Req g minus delivered) | +4.9 pp | +4.6 pp | 4th most demanding of 8 |
| ROIC minus cost of capital | +7.3 pp | -5.6 pp | 2nd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | n/a | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |